Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.

Published on Sep 1, 2018in Anticancer Research2.48
· DOI :10.21873/ANTICANRES.12868
Kosuke Ueda7
Estimated H-index: 7
(Kurume University),
Shigetaka Suekane21
Estimated H-index: 21
(Kurume University)
+ 7 AuthorsTsukasa Igawa17
Estimated H-index: 17
(Kurume University)
AIM: To investigate prognostic factors for patients with advanced renal cell carcinoma (RCC) treated with axitinib as second-line therapy. PATIENTS AND METHODS: This study included 35 patients with RCC who received axitinib as second-line therapy after the failure of first-line tyrosine kinases inhibitor from November 2012 to March 2017. RESULTS: In univariate analyses, the following factors were associated with poor prognosis: bone and extrapulmonary metastasis for progression-free survival; and prior nephrectomy, Memorial Sloan Kettering Cancer Center risk classification, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification of poor, extrapulmonary metastasis and early tumor response for overall survival. Multivariate analyses identified the following factors as independent poor prognostic effects: extrapulmonary metastasis for progression-free survival, and no prior nephrectomy, IMDC risk classification of poor and extrapulmonary metastasis for overall survival. CONCLUSION: Axitinib as second-line treatment is effective for patients with pulmonary metastasis alone of RCC, but not for those with extrapulmonary metastasis.
Cited By6
#1Gu-Shun LaiH-Index: 1
#2Jian-Ri LiH-Index: 15
Last. Kun-Yuan ChiuH-Index: 11
view all 9 authors...
BACKGROUND/AIM To investigate the prognostic values of fat invasion (FI) and renal vein invasion (RVI) in pT3a renal cell carcinoma (RCC), as single factors or concomitant presence. PATIENTS AND METHODS We retrospectively reviewed the data of 173 patients who underwent radical or partial nephrectomy for RCC in our Institution. RESULTS At a median follow-up time of 48 months, patients with RVI showed significantly increased risk of disease recurrence and worse cancer-specific survival (CSS) when ...
#1Kazuyuki Numakura (Akita University)H-Index: 19
#2Mizuki Kobayashi (Akita University)H-Index: 1
Last. Tomonori Habuchi (Akita University)H-Index: 65
view all 13 authors...
Axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, will be used in combination first-line therapies against metastatic renal cell carcinoma (mRCC), but its effects as a first-line monotherapy are unclear. Thus, we aimed to elucidate pretreatment clinical factors that predict the prognosis of patients with mRCC receiving first-line axitinib therapy. We enrolled 63 patients with mRCC treated with axitinib as first-line therapy between Nov. 2003 and Jul. 2018. Progre...
#1Takahiro Osawa (Hokkaido University)H-Index: 16
#2Takahiro Kojima (University of Tsukuba)H-Index: 15
Last. Nobuo Shinohara (Hokkaido University)H-Index: 48
view all 43 authors...
: The present study aimed to evaluate the efficacy of the real-world use of axitinib and to develop a prognostic model for stratifying patients who could derive long-term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with one or two systemic anti-angiogenic therapy regimens at one of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and Fe...
#1Nobuyuki Hinata (Kobe University)H-Index: 17
#2Junji YoneseH-Index: 27
Last. Hirotsugu Uemura (Kindai University)H-Index: 36
view all 20 authors...
BACKGROUND In a phase III clinical trial, CheckMate 025, treatment of metastatic renal cell carcinoma (mRCC) with nivolumab demonstrated superior efficacy over everolimus. However, as the clinical trial excluded patients with specific complications and poor performance status (PS), the effectiveness and safety of nivolumab in clinical practice, in which patients with various clinical complications are treated, is unclear. This study explored real-world nivolumab treatment in Japanese mRCC patien...
#1Nizar M. Tannir (University of Texas MD Anderson Cancer Center)H-Index: 72
#2Thomas Powles (QMUL: Queen Mary University of London)H-Index: 92
Last. Toni K. Choueiri (Harvard University)H-Index: 120
view all 16 authors...
#1Roopa Thapar (University of Texas MD Anderson Cancer Center)H-Index: 18
#2Albino Bacolla (University of Texas MD Anderson Cancer Center)H-Index: 35
Last. John A. Tainer (University of Texas MD Anderson Cancer Center)H-Index: 135
view all 7 authors...
An emerging molecular understanding of RNA alkylation and its removal is transforming our knowledge of RNA biology and its interplay with cancer chemotherapy responses. DNA modifications are known to perform critical functions depending on the genome template, including gene expression, DNA replication timing, and DNA damage protection, yet current results suggest that the chemical diversity of DNA modifications pales in comparison to those on RNA. More than 150 RNA modifications have been ident...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.